Usha Malhotra, MD

Advanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.

Several agents targeting the hedgehog pathway are under preclinical and clinical evaluation. In this article, we describe various classes of these agents and the evidence supporting their anticancer activity.